Therapeutic Class Distribution of Cancer Vaccines
- There are currently 915+ cancer vaccine assets in development. Cellular, peptide, nucleic acid-based and viral vaccines comprise 86% of the total cancer vaccine landscape. The remaining 14% (grouped as ‘Other Vaccine Class’) is made up of assets with an unspecified vaccine class (6%), protein vaccines (5%), bacterial vaccines (3%) and yeast vaccines (<1%).
Drug Status of Cancer Vaccines
The majority of cancer vaccines on Beacon are currently active; 60% of assets have entered clinical trials, and just under a quarter are in preclinical development.
The space has seen eight approvals – half of which are prophylactic viral vaccines targeting HPV associated cancers, most noticeably Gardasil, Gardasil 9 and Cervarix which have received FDA and EMA approval.
The cancer vaccine landscape is currently dominated by cellular, peptide, nucleic acid-based and viral vaccines. The cellular vaccine class largely comprises dendritic cell vaccines due to the established nature of the field. Within nucleic acid-based vaccines, the space has currently shifted towards DNA vaccines, although this paradigm is likely to change given the recent successes of SARS-CoV-2 mRNA vaccines.
Half of approved assets are prophylactic viral vaccines for HPV associated cancer, with other vaccines classes gaining approvals but to a more limited extent.
Most cancer vaccines in the clinic are in phase 1 or 2 trials, although the large proportion of completed and active trials suggest this is a space that will continue to grow.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements